5.1.4 Gene therapy and genome editing Recent advances in gene therapy and genome editing offer promising approaches to modulate ferroptosis in OA by targeting critical regulators such as GPX4, SLC7A11, and epigenetic modifiers
GS-4997 is an oral ASK1 inhibitor and a randomized, double-blind, open phase II clinical trial in patients with MASH and fibrosis is currently underway to evaluate the efficacy of 24 weeks of treatment with GS-4997 or GS-4997 and simtuzumab
Patients taking an evening dosage of metformin HCl extended-release should skip their last dose before starting XIGDUO XR
Patients with a history of pancreatitis, particularly those with chronic pancreatitis or recurrent acute episodes, may be at increased risk for pancreatitis recurrence or exacerbation
down from a record high of nearly 40% in 2022
You receive a clear yes/no recommendation